How Do Doctors Personalize Multiple Myeloma Treatment? Risk, MRD & More

Description

Dr. Sarvari Yellapragada of MD Anderson Cancer Center explains how myeloma specialists personalize treatment using disease factors, patient factors, and patient goals, shared at the HealthTree Houston Myeloma Roundtable (October 24, 2026). She sorts the myeloma toolbox by drug class (proteasome inhibitors, IMiDs and CELMoDs, CD38 antibodies, CAR-T, bispecific antibodies, belantamab, selinexor), reviews the ISS, R-ISS and IMS/IMWG high-risk genetics, plasma cell leukemia and extramedullary disease, and shows how MRD testing (flow cytometry, next-generation sequencing, imaging) guides decisions. She also covers frailty, comorbidities, the "three talk" shared decision model, sequencing therapies, fixed-duration treatment, and access barriers.